Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2008

View Archived Issues

Recent Daiichi Sankyo patent discloses novel immunosuppressant agents

Targeting ASICs may provide benefit in multiple sclerosis

Endo to develop and commercialize Alexza's AZ-003 Staccato inhaled fentanyl

Northwest Biotherapeutics commences ovarian cancer clinical trial with DCVax-L

U.K. report cites Hemispherx's Ampligen as a potential aid for CFS

Interim safety analysis supports continuation of phase II PROPEL trial

Patient accrual completed in phase II nimotuzumab trial in colorectal cancer

Phase IIa MEM-3454 trial begins for cognitive impairment in schizophrenia

Theravance receives notice of possible telavancin review

Preclinical studies suggest K+ channel TASK-1 to be potential target of antiepileptic drugs

Wide therapeutic potential seen for sanofi-aventis' GlyT-1 inhibitor SSR-103800

Millennium receives material sales milestone for Velcade

MorphoSys submits CTA for phase I HuCAL-derived antibody trial

Par Pharmaceutical provides update on pipeline products

Recent patents describe novel therapeutic agents for respiratory disorders

Novel treatment option for hepatitis C virus infection disclosed in recent patents

Phase I ADL-5747 trial for treatment of pain to be initiated shortly under IND

Cephalon submits NDA to FDA for Treanda for relapsed indolent non-Hodgkin's lymphoma

Forest and Cypress submit NDA to FDA for milnacipran for fibromyalgia syndrome

Sanofi-aventis discontinues participation with IDM Pharma on the development of Uvidem

Salix submits NDA to FDA for granulated mesalamine for remission of ulcerative colitis

Cyclacel initiates phase II clinical trial of sapacitabine in elderly patients with AML